The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants second approval to tisagenlecleucel (Kymriah) for the treatment of R/R large B-cell lymphoma
On 01 May 2018, it was announced in a press release that the US Food and Drug Administration (FDA) approved the Novartis CAR-T therapy, tisagenlecleucel (Kymriah), as an intravenous suspension for its second indication for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and transformed follicular lymphoma (tFL). This therapy is targeted to patients who do not respond to second or later line therapy, including autologous stem cell transplantation. Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma (PCNSL).
This CAR-T therapy received its first FDA approval in August 2017 for the treatment of pediatric and young adult R/R acute lymphoblastic leukemia (ALL) patients who do not respond to second or later line treatment.
Stephen Schuster, Professor at Penn Medicine and Director of the Lymphoma Program at the Abramson Cancer Center commented that "with this approval, physicians now have a meaningful therapeutic option that can achieve and maintain a sustained response without stem cell transplant along with a consistent safety profile."